Log In
Print this Print this

IDegLira, Xultophy, insulin degludec/liraglutide (NN9068)

Also known as: Victoza-Degludec combination product

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionFixed-dose combination of Victoza liraglutide, a long-acting analog of glucagon-like peptide-1 (GLP-1), and Tresiba insulin degludec, a long-acting insulin analog
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat diabetes and obesity; Treat Type II diabetes
Regulatory Designation EU - Standard Review (Treat Type II diabetes);
Switzerland - Standard Review (Treat Type II diabetes)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today